Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Avita Taps Sinopharm To Ramp-Up China Sales Of ReCell "Spray-On-Skin"

Executive Summary

Avita Medical has awarded Sinopharm with exclusive rights to distribute across China ReCell, an autologous cell harvesting device that creates a cellular suspension made from the patient’s own skin for use in advanced wound care and the treatment of skin defects. This "spray-on-skin" can be used in conjunction with all other key wound care approaches and is currently in a multi-center pivotal trial to obtain US FDA premarket approval, which is expected in Q3 2017.



Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst